Business Context and Reporting Period
This Form 10-Q covers Schering-Plough Corporation for the quarterly and nine-month periods ended September 30, 1997. The company operates primarily in pharmaceutical and health care products. A significant corporate event during this period was the acquisition of the worldwide animal health business of Mallinckrodt Inc. on June 30, 1997, for approximately $490 million. Additionally, the company completed a 2-for-1 stock split in June 1997.
Key Financial Metrics
| Metric (in millions) | Q3 1997 | Q3 1996 | 9M 1997 | 9M 1996 |
|---|---|---|---|---|
| Sales | $1,709 | $1,383 | $4,997 | $4,242 |
| Net Income | $353 | $291 | $1,101 | $935 |
| Earnings Per Share | $0.48 | $0.39 | $1.50 | $1.27 |
| Operating Cash Flow (9M) | $1,362 (1997) vs $1,030 (1996) | |||
| Cash and Equivalents | $732 (Sep 30, 1997) vs $535 (Dec 31, 1996) | |||
| Total Debt (Short + Long Term) | $825 (Sep 30, 1997) vs $901 (Dec 31, 1996) | |||
| Effective Tax Rate | 24.5% (Both periods) |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated sales increased 24% in Q3 and 18% for the nine-month period compared to 1996. Excluding foreign currency fluctuations, growth was 27% (Q3) and 21% (9M).
- Profitability: Net income rose 21% in Q3 and 18% for the nine-month period. Income before taxes represented 27.3% of sales in Q3 (down slightly from 27.9% in 1996) and 29.2% for the nine-month period (flat vs. 1996).
- Acquisition Impact: The Mallinckrodt animal health acquisition contributed $78 million in sales for Q3. Without this acquisition, Q3 sales would have grown 14%.
- Product Performance:
- CLARITIN: Drove significant growth in allergy/respiratory sales ($448M in Q3, $1.3B in 9M).
- PROVENTIL: Sales declined 18% for the nine-month period due to generic competition, despite a quarterly increase driven by trade buying patterns.
- INTRON A: Increased sales in anti-infective/anticancer segments.
- Expense Ratios: R&D spending increased 21% in Q3 (12.9% of sales) and 16% for 9M (12.2% of sales). SG&A expenses as a percentage of sales increased slightly for the nine-month period (39.1% vs 38.8%) due to higher promotional spending for CLARITIN and INTRON A.
Guidance, Outlook, Risks, and Contingencies
- Share Repurchases: The company is approximately 85% complete with a $500 million repurchase program authorized in September 1996. A new $1 billion repurchase program was authorized in September 1997.
- Legal Proceedings: The company is a defendant in over 160 antitrust actions. A federal class action was settled for $22.1 million payable over three years. In August 1997, the Seventh Circuit Court of Appeals reversed a summary judgment granted to wholesalers, potentially expanding liability exposure for indirect purchasers, though the immediate effect is limited to cases where wholesalers were not named as defendants.
- Regulatory Risks: The company faces uncertainty regarding regulatory approval for CLARITIN in Japan, which is not expected in 1997. Government-mandated cost containment and price cuts in international markets remain a risk.
- Competitive Landscape: Generic competition continues to negatively affect the PROVENTIL line. Patent disputes and technological advances by competitors pose ongoing risks.
- Accounting Changes: The company will adopt SFAS No. 128 (Earnings Per Share) and SFAS No. 130/131 (Comprehensive Income/Segment Reporting) in 1998.
Investor Verification Checklist
- Verify the final allocation of the $490 million Mallinckrodt acquisition purchase price pending fair value studies.
- Monitor the status of the 160+ antitrust lawsuits, specifically the impact of the Seventh Circuit's reversal on indirect purchaser claims.
- Track the timeline for CLARITIN regulatory approval in Japan and its potential revenue impact.
- Assess the long-term erosion of PROVENTIL sales due to generic competition versus the success of the new PROVENTIL HFA launch.
- Confirm the execution timeline and volume of the new $1 billion share repurchase program.